What does tumor mutational burden (TMB) mean for Non-Small Cell Lung Cancer

Understanding Tumor Mutational Burden (TMB) in NSCLC

What TMB Measures

Tumor mutational burden (TMB) is a count of the total number of mutations (genetic changes) found in your cancer cells. Think of it as measuring how many "errors" or changes exist in the DNA of your tumor. TMB is typically measured as the number of mutations per million base pairs of tumor DNA.

In practical terms: A higher TMB means your cancer cells have accumulated more genetic mutations. According to NCCN Guidelines, TMB-high (TMB-H) is generally defined as 10 or more mutations per million base pairs.

The Original Theory (Why Doctors Were Interested)

The initial reasoning made sense: doctors theorized that tumors with more mutations would produce more "neoantigens" (foreign proteins that the immune system could recognize). This suggested that patients with high TMB might respond better to immunotherapy drugs like pembrolizumab or nivolumab, which work by "releasing the brakes" on the immune system.

What the Evidence Actually Shows

Here's where it gets important: The clinical data doesn't support using TMB as a reliable predictor for NSCLC patients.

According to the NCCN Guidelines for NSCLC:

• High TMB doesn't reliably predict immunotherapy response. The CHECKMATE 227 trial showed that overall survival improved with nivolumab plus ipilimumab regardless of TMB levels or PD-L1 expression levels
• High TMB doesn't correlate with PD-L1 expression. Several trials demonstrated that patients with high TMB don't necessarily have high PD-L1 levels, and vice versa
• Some patients with low TMB respond to immunotherapy, while some with high TMB don't. TMB is simply not a consistent predictor of who will benefit
• TMB has technical problems. There's no standardized way to measure it across different laboratories, and there's disagreement about what cutoff value should define "high" TMB

Current Clinical Recommendation

The NCCN Panel removed TMB as an emerging immune biomarker in 2020 for patients with metastatic NSCLC. The guidelines now state: "The NCCN NSCLC Panel does not recommend measurement of TMB levels before deciding whether to use nivolumab plus ipilimumab regimens or to use other ICIs."

What IS Still Recommended Instead

According to NCCN Guidelines, PD-L1 expression testing is currently the better biomarker for deciding about immunotherapy because:

• Results are obtained more quickly
• Less tissue is needed for testing
• Data show better reproducibility across different labs and platforms

Additionally, the NCCN Panel emphasizes that clinicians should test for actionable driver mutations (like EGFR, ALK, BRAF, KRAS, RET, ROS1, and others) before starting first-line immunotherapy, because targeted therapies for these mutations typically work better than immunotherapy alone.

Questions to Ask Your Oncologist

If TMB testing was done on your tumor, consider asking:

1. "What was my TMB result, and what does it mean for my specific treatment plan?" (Even though it's not routinely used for decisions, your doctor may have ordered it and can explain the context)
2. "What biomarkers are most important for deciding my treatment—specifically my PD-L1 level and any driver mutations?"
3. "Based on my specific biomarkers and cancer stage, what treatment approach do you recommend?"
4. "Will my treatment plan change based on any of these test results?"

The Bottom Line

TMB is an interesting measure of tumor genetics, but it's not reliable enough to guide treatment decisions in NSCLC. Your oncologist will focus on more predictive biomarkers like PD-L1 expression and driver mutations (EGFR, ALK, BRAF, etc.) to determine whether immunotherapy, targeted therapy, or chemotherapy is most appropriate for your specific situation.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.